New hope for AML patients too frail for harsh chemo: milder drug combo aims to wipe out cancer cells fast
NCT ID NCT07236931
First seen Nov 19, 2025 · Last updated May 23, 2026 · Updated 24 times
Summary
This study tests a new treatment plan for adults with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy. The approach uses a drug called selinexor, either alone or with very low doses of other chemo drugs, to quickly reduce cancer cells in the blood and bone marrow. The goal is to improve survival while causing fewer side effects. About 71 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML - ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, 430000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.